Long-term safety of lamivudine treatment in patients with chronic hepatitis B
Top Cited Papers
- 1 December 2003
- journal article
- clinical trial
- Published by Elsevier BV in Gastroenterology
- Vol. 125 (6), 1714-1722
- https://doi.org/10.1053/j.gastro.2003.09.033
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonrespondersJournal of Hepatology, 2003
- Histological outcome during long-term lamivudine therapyGastroenterology, 2003
- Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapyHepatology, 2001
- Effects of extended lamivudine therapy in Asian patients with chronic hepatitis BGastroenterology, 2000
- Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trialGut, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.Journal of General Virology, 1999
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defectiveHepatology, 1998